Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

INBX

+ Watchlist+ Portfolio

Inhibrx Biosciences, Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$74.18
52-Week Range
$57.30 – $155.29
Market Cap
$1.02B
P/E (TTM)
—
EPS (TTM)
-9.06
Dividend Yield
0.00%
Advanced Metrics
Price/Book
—
PEG Ratio
—
Return on Equity
—
Return on Assets
-39.51%
Gross Margin
0.00%
Operating Margin
-6286.70%
Profit Margin
0.00%
Current Ratio
7.58
Debt/Equity
—
Total Debt
$281.44M
Free Cash Flow
$-81.11M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$1.10B

Market Snapshot

About

Inhibrx Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines for oncology. The company's lead program targets alpha-fetoprotein (AFP)-positive tumors, including hepatocellular carcinoma, using a novel T cell engager platform. Inhibrx Biosciences leverages its proprietary single-domain antibody technology to create multi-specific therapeutics designed to redirect immune cells to tumor sites. The company's pipeline includes programs addressing difficult-to-treat solid tumors with high unmet medical needs.